Skip to content
2000
image of Comprehensive Meta-Analysis on the Impact of the MDM2 SNP 309 T>G Gene Variant in Leukemia Susceptibility

Abstract

Introduction

Genetic factors play a significant role in the development of leukemia. The overexpression of MDM2 is associated with the progression of certain leukemias. This meta-analysis investigates the relationship between the SNP 309T>G and various forms of leukemia across global populations.

Methods

A comprehensive literature search was conducted to retrieve genotyping data from twenty case-control studies related to SNP 309T>G polymorphism and leukemia. A random-effects model was used to calculate the pooled odds ratio (OR) and 95% confidence interval (95% CI) for the association analysis. MetaGenyo software was utilized to conduct statistical analyses in this meta-analysis.

Results

The findings indicate a significant association between 309 SNPT>G polymorphism and leukemia in Asian and Caucasian populations. Additionally, this polymorphism is associated with an increased risk of Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML), implying that may play a role in the pathogenesis of these specific forms of leukemia.

Conclusion

This meta-analysis suggests that may represent a susceptibility gene for leukemia risk.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128368759250527073556
2025-07-23
2025-09-10

  • From This Site

    /content/journals/cpd/10.2174/0113816128368759250527073556
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Whiteley A.E. Price T.T. Cantelli G. Sipkins D.A. Leukaemia: A model metastatic disease. Nat. Rev. Cancer 2021 21 7 461 475 10.1038/s41568‑021‑00355‑z 33953370
    [Google Scholar]
  2. Bispo J.A.B. Pinheiro P.S. Kobetz E.K. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb. Perspect. Med. 2020 10 6 a034819 10.1101/cshperspect.a034819 31727680
    [Google Scholar]
  3. Yan Y.L. Han F. Tan W.M. Wu C.P. Qin X. Association between the MDM2 T309G polymorphism and leukemia risk: A meta-analysis. Asian Pac. J. Cancer Prev. 2014 15 16 6767 6772 10.7314/APJCP.2014.15.16.6767 25169523
    [Google Scholar]
  4. Cingeetham A. Vuree S. Jiwatani S. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development. Asian Pac. J. Cancer Prev. 2015 16 7 2707 2712 10.7314/APJCP.2015.16.7.2707 25854351
    [Google Scholar]
  5. Merchant N. Bandaru S.S. Alam A. Bhaskar L.V.K.S. The correlation between MDM2 SNP309 T > G polymorphism and hepatocellular carcinoma risk - A meta-analysis. Hum. Genet. 2022 34 201087 10.1016/j.humgen.2022.201087
    [Google Scholar]
  6. Lessel D. Wu D. Trujillo C. Dysfunction of the MDM2/p53 axis is linked to premature aging. J. Clin. Invest. 2017 127 10 3598 3608 10.1172/JCI92171 28846075
    [Google Scholar]
  7. Tseng A. Seet J. Phillips E.J. The evolution of three decades of antiretroviral therapy: Challenges, triumphs and the promise of the future. Br. J. Clin. Pharmacol. 2015 79 2 182 194 10.1111/bcp.12403 24730660
    [Google Scholar]
  8. He X. Chen P. Yang K. Association of MDM2 polymorphism with risk and prognosis of leukemia: A meta-analysis. Acta Haematol. 2015 133 4 365 371 10.1159/000369522 25790771
    [Google Scholar]
  9. Zhuo W. Zhang L. Ling J. Zhu B. Chen Z. MDM2 SNP309 variation contributes to leukemia risk: Meta-analyses based on 7259 subjects. Leuk. Lymphoma 2012 53 11 2245 2252 10.3109/10428194.2012.691485 22563815
    [Google Scholar]
  10. Zhao D Liu T. The relationship between MDM2 T309G polymorphism and leukemia in the chinese population: Evidence from a meta-analysis. Clin Lab 2017 63 10/2017 1639 1645
    [Google Scholar]
  11. Moher D. Liberati A. Tetzlaff J. Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009 6 7 1000097 10.1371/journal.pmed.1000097 19621072
    [Google Scholar]
  12. Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010 25 9 603 605 10.1007/s10654‑010‑9491‑z 20652370
    [Google Scholar]
  13. Martorell-Marugan J. Toro-Dominguez D. Alarcon-Riquelme M.E. Carmona-Saez P. MetaGenyo: A web tool for meta-analysis of genetic association studies. BMC Bioinformatics 2017 18 1 563 10.1186/s12859‑017‑1990‑4 29246109
    [Google Scholar]
  14. Zenz T. Häbe S. Benner A. Kienle D. Döhner H. Stilgenbauer S. The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica 2008 93 7 1111 1113 10.3324/haematol.12738 18508789
    [Google Scholar]
  15. Phang B.H. Linn Y.C. Li H. Sabapathy K. MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients. Eur. J. Cancer 2008 44 5 760 766 10.1016/j.ejca.2008.02.007 18313915
    [Google Scholar]
  16. Ellis N.A. Huo D. Yildiz O. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008 112 3 741 749 10.1182/blood‑2007‑11‑126508 18426989
    [Google Scholar]
  17. Chen Y.L. Chang Y.S. Chang J.G. Wu S.M. Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal. Bioanal. Chem. 2009 394 5 1291 1297 10.1007/s00216‑008‑2416‑y 19015838
    [Google Scholar]
  18. Xiong X. Wang M. Wang L. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk. Res. 2009 33 11 1454 1458 10.1016/j.leukres.2009.04.007 19423162
    [Google Scholar]
  19. Do T.N. Ucisik-Akkaya E. Davis C.F. Morrison B.A. Dorak M.T. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet. Cytogenet. 2009 195 1 31 36 10.1016/j.cancergencyto.2009.05.009 19837266
    [Google Scholar]
  20. Phillips C.L. Gerbing R. Alonzo T. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: A report from the Children’s Oncology Group. Pediatr. Blood Cancer 2010 55 2 248 253 10.1002/pbc.22519 20582981
    [Google Scholar]
  21. Dong H.J. Fang C. Fan L. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL. Int. J. Cancer 2012 130 9 2054 2061 10.1002/ijc.26222 21647873
    [Google Scholar]
  22. Ebid G.T. Sedhom I.A. El-Gammal M.M. Moneer M.M. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia. Asian Pac. J. Cancer Prev. 2012 13 9 4315 4320 10.7314/APJCP.2012.13.9.4315 23167335
    [Google Scholar]
  23. Chen J. Zhu B. Chen J. Li Y. Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population. DNA Cell Biol. 2013 32 7 414 419 10.1089/dna.2012.1900 23745682
    [Google Scholar]
  24. Liu Y.C. Hsiao H.H. Yang W.C. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: The association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib. Mol. Carcinog. 2014 53 12 951 959 10.1002/mc.22061 23818300
    [Google Scholar]
  25. El-Danasouri N.M. Ragab S.H. Rasheed M.A. Ali El Saadany Z. Abd El-Fattah S.N. MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: An Egyptian study. Ann. Clin. Lab. Sci. 2014 44 4 449 454 25361931
    [Google Scholar]
  26. Falk I.J. Willander K. Chaireti R. TP 53 mutations and MDM2SNP309 identify subgroups of AML patients with impaired outcome. Eur. J. Haematol. 2015 94 4 355 362 10.1111/ejh.12438 25156865
    [Google Scholar]
  27. Soleymannejad M. Sheikhha M.H. Neamatzadeh H. Association of mouse double minute 2-309t>g polymorphism with acute myeloid leukemia in an iranian population: A case- control study. Asian Pac. J. Cancer Prev. 2019 20 10 3037 3041 10.31557/APJCP.2019.20.10.3037 31653152
    [Google Scholar]
  28. Lotfi Garavand A. Mohammadi M. Mohammadzadeh S. Evaluation of TP53 Codon 72, P21 Codon 31, and MDM2 snp309 polymorphisms in iranian patients with acute lymphocytic leukemia. Rep. Biochem. Mol. Biol. 2020 9 1 26 32 10.29252/rbmb.9.1.26 32821748
    [Google Scholar]
  29. Tripon F. Iancu M. Trifa A. Association Analysis of TP53 rs1042522, MDM2 rs2279744, rs3730485, MDM4 rs4245739 variants and acute myeloid leukemia susceptibility, risk stratification scores, and clinical features: An exploratory study. J. Clin. Med. 2020 9 6 1672 10.3390/jcm9061672 32492903
    [Google Scholar]
  30. Jalilian N. Maleki Y. Shakiba E. p53 p.Pro72Arg (rs1042522) and mouse double minute 2 (MDM2) single-nucleotide polymorphism (SNP) 309 variants and their interaction in chronic lymphocytic leukemia(CLL): A survey in CLL patients from western iran. Int. J. Hematol. Oncol. Stem Cell Res. 2021 15 3 160 169 10.18502/ijhoscr.v15i3.6846 35082997
    [Google Scholar]
  31. Benseddik K. Abderrahmane R. Boudjemaa A. Association of TP53 P72R and MDM2 SNP309 variants with susceptibil-ity to chronic myeloid leukaemia development in Algerian population: TP53 P72R C allele is a strong risk marker and MDM2 SNP309 G allele has a protective effect. South Asian J. Exp. Biol. 2022 12 1 28 34 10.38150/sajeb.12(1).p28‑34
    [Google Scholar]
  32. Karni-Schmidt O. Lokshin M. Prives C. The roles of MDM2 and MDMX in cancer. Annu. Rev. Pathol. 2016 11 1 617 644 10.1146/annurev‑pathol‑012414‑040349 27022975
    [Google Scholar]
  33. Wang W. Du M. Gu D. MDM2 SNP309 polymorphism is associated with colorectal cancer risk. Sci. Rep. 2014 4 1 4851 10.1038/srep04851 24797837
    [Google Scholar]
  34. Miedl H. Lebhard J. Ehart L. Schreiber M. Association of the MDM2 SNP285 and SNP309 genetic variants with the risk, age at onset and prognosis of breast cancer in central european women: A hospital-based case-control study. Int. J. Mol. Sci. 2019 20 3 509 10.3390/ijms20030509 30691044
    [Google Scholar]
  35. Wan Y. Wu W. Yin Z. Guan P. Zhou B. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: An updated meta-analysis. BMC Cancer 2011 11 1 208 10.1186/1471‑2407‑11‑208 21619694
    [Google Scholar]
  36. Ou W.B. Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia. Med. Sci. Monit. 2015 21 213 218 10.12659/MSM.892919 25600314
    [Google Scholar]
  37. Siqian Lu W.T. Luo Y. MDM2 309 T/G Polymorphism Is Associated With Acute Myeloid Leukemia: A MetaAnalysis. Int J Sci Res Environ Sci Toxicol 2017 217 2 1 5
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128368759250527073556
Loading
Comprehensive Meta-Analysis on the Impact of the MDM2 SNP 309 T>G Gene Variant in Leukemia Susceptibility
Bentham Science Publishers ; https://doi.org/10.2174/0113816128368759250527073556
/content/journals/cpd/10.2174/0113816128368759250527073556
/content/journals/cpd/10.2174/0113816128368759250527073556
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: AML ; leukemia ; CML ; meta-analysis ; MDM2 309 SNP T>G ; rs2279744

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test